Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
1. Lexicon Pharmaceuticals presents data on diabetic neuropathic pain at PAINWeek 2025. 2. Approximately 25-30% of diabetes patients suffer from diabetic peripheral neuropathic pain. 3. Pilavapadin, a novel treatment, targets neuropathic pain without affecting opiate pathways. 4. The drug received FDA Fast Track designation for DPNP treatment development. 5. Lexicon's genomic platform aids in discovering new drug targets for various diseases.